Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
point decrease » point increase (Expand Search)
1 point » _ point (Expand Search), 3d point (Expand Search), _ points (Expand Search)
increase » increased (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
point decrease » point increase (Expand Search)
1 point » _ point (Expand Search), 3d point (Expand Search), _ points (Expand Search)
increase » increased (Expand Search)
-
1
-
2
-
3
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025Subjects: -
4
-
5
-
6
-
7
-
8
TITAN thresholds and percentile estimates for benthic macroinvertebrate and diatom communities deemed to be sensitive decreasers or tolerant increasers. The thresholds represent the largest fsum <i>z</i> value in the main data analysis run (i.e., the median), whereas the 5<sup>th</sup> and 95<sup>th</sup> percentile change points are determined from 500 bootstrap replicate runs. Sensitive taxa change points derived from decreaser sum <i>z</i>- relative to increasing impervious cover (I.C.; %), specific conductivity (SpCond; μS cm<sup>-1</sup>), total nitrogen (TN; μg L<sup>-1</sup>), and total phosphorus (TP; μg L<sup>-1</sup>)....
Published 2025“…Sensitive taxa change points derived from decreaser sum <i>z</i>- relative to increasing impervious cover (I.C.; %), specific conductivity (SpCond; μS cm<sup>-1</sup>), total nitrogen (TN; μg L<sup>-1</sup>), and total phosphorus (TP; μg L<sup>-1</sup>). …”
-
9
-
10
-
11
<sup>1</sup>H NMR spectra for kylo-0603.
Published 2025“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”
-
12
Withdrawal of Type I JAKinibs increased STAT phosphorylation, a phenomenon present but markedly lower in Type II JAKinibs.
Published 2025“…(A) pJAK2 peaked at time zero after exposure to baricitinib and ruxolitinib and then decreases. There was no increase in pJAK2 with CHZ868 treatment; (B) pSTAT1 proportion peaked after 60 minutes and was greater after Type I JAKinib withdrawal than Type II JAKinib withdrawal; <b>(C)</b> The pSTAT2 proportion peaked 60 minutes after Type I JAKinib withdrawal but this phenomenon was not seen with Type II JAKinib withdrawal.…”
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20